Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 20OTHER 11NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 9Disease 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Vinorelbine 4Dexamethasone 4Filgrastim 3Vincristine 2Peripheral Blood Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Fenretinide 2Etoposide 2Cytarabine 2Carmustine 2Bortezomib 2zanubrutinib 1relatlimab 1pomalidomide 1pegaspargase 1palbociclib 1liposomal amphotericin B 1ixazomib 1irinotecan sucrosofate 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1etoposide phosphate 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Recurrence × carfilzomib × Clear all
NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

SWOG Cancer Research Network

Phase 2 Completed
143 enrolled 14 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡